WHAT THEY ARE SAYING: LOWERING Rx PRICES & HOLDING BIG PHARMA ACCOUNTABLE TOP PRIORITY IN 2020

Editorial Boards, Lawmakers and More Reiterate Need for Market-Based Solutions to Out-of-Control Prescription Drug Prices in 2020 Right on cue, Big Pharma kicked off the New Year by raising prices

01-14-2020 Read More

BIG PHARMA WATCH: HEADLINES FROM BIG PHARMA’S 2020 PRICE HIKE BONANZA

News from First Weeks of New Year Underscores Urgent Need for Action in Congress In case you missed it, Big Pharma has hiked prices on 2,167 prescription drugs so far this year – proving once

01-13-2020 Read More

CSRXP: BIG PHARMA THUMBS ITS NOSE AT STRUGGLING AMERICANS WITH NEW YEAR PRICE HIKES

Drug Makers, Including Brand Name Giants Like Pfizer, Increase Prices on More Than 200 Prescription Drugs Despite Mounting Crisis of Affordability For Immediate Release Contact: Jon Conradi

01-2-2020 Read More

CSRXP APPLAUDS INCLUSION OF CREATES IN SPENDING DEAL; URGES CONGRESS TO KEEP WORKING TO HOLD BIG PHARMA ACCOUNTABLE, LOWER Rx PRICES

Passage of Bipartisan, Market-based CREATES Act Will Be A First Step in the Right Direction But Patients Need Washington to Do Much More  For Immediate Release Contact: Jon Conradi 860-235-3884

12-16-2019 Read More

Big Pharma’s Price-Gouging and Anti-Competitive Tactics Drive Increased Rx Spending

CMS Report Demonstrates Impact of Out-of-Control Launch Prices and Tactics That Prevent Patients From Accessing Affordable Alternatives In case you missed it, according to the Centers for Medicare

12-13-2019 Read More

CSRXP: THE HOUSE HAS ACTED, TIME FOR SENATE TO DO ITS JOB

Passage of HR3 Adds to Momentum to Hold Big Pharma Accountable; Now Congress Must Move Swiftly to Get Bipartisan Reforms Passed into Law For Immediate Release Contact: Jon Conradi 860-235-3884

12-12-2019 Read More

CSRXP APPLAUDS USMCA CHANGES TO PUT AMERICAN PATIENTS FIRST

Revisions to Historic Trade Deal Remove Big Pharma Carveout For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing

12-10-2019 Read More

CSRXP ANALYSIS: BIG PHARMA SPENT TAX WINDFALL ON PROFITS, NOT R&D

Corporate Filings Show Drug Makers Boosted Payouts for Shareholders 17 Times More Than Increased Investment in ‘Innovation’ For Immediate Release Contact: Jon Conradi 860-235-3884

12-10-2019 Read More

BIG PHARMA WATCH: NEW STUDY FINDS PRICE HIKES DRIVEN BY QUEST FOR HIGHER PROFITS, NOT R&D

Analysis of Multiple Sclerosis Drug Pricing Undercuts Drug Makers’ Bogus “Innovation” Rhetoric A new study published in the American Academy of Neurology finds the staggering price of

12-4-2019 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.